AKR1B1 and diabetes mellitus: The addition of an aldose reductase inhibitor 3 weeks after induction of diabetes reversed defects in choline acetyltransferase axonal transport and motor nerve conduction velocity (220, 233–235), which may be related to the promotion of actin slow component B (SCb) and βtubulin (SCb) in DM rats (236).